Stock Events

Orphazyme A/S 

$90
15
+$0+0% Monday 20:00

Statistics

Day High
0.09
Day Low
0.09
52W High
150
52W Low
0.09
Volume
3,250
Avg. Volume
0
Mkt Cap
3,178
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

26SepExpected
Q2 2019
Q4 2019
Q2 2020
Q4 2020
Q2 2021
Q1 2022
Q2 2022
-5.28
-4.95
-4.61
-4.28
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OZYMF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap32.96B
Biogen is a biotech firm with a strong focus on neurodegenerative diseases, similar to Orphazyme's focus on rare diseases.
Vertex Pharmaceuticals
VRTX
Mkt Cap126.85B
Vertex Pharmaceuticals is involved in treating cystic fibrosis, a rare disease, showing its capability and interest in the rare disease market.
Alnylam Pharmaceuticals
ALNY
Mkt Cap30.08B
Alnylam Pharmaceuticals focuses on RNAi therapeutics for rare genetic diseases, aligning with Orphazyme's rare disease treatment goals.
Sarepta Therapeutics
SRPT
Mkt Cap13.76B
Sarepta Therapeutics specializes in the treatment of rare genetic diseases, particularly in the area of Duchenne muscular dystrophy.
Ionis Pharmaceuticals
IONS
Mkt Cap6.98B
Ionis Pharmaceuticals is a leader in RNA-targeted drug discovery and development, working on treatments for rare diseases.
Biomarin Pharmaceutical
BMRN
Mkt Cap15.97B
BioMarin Pharmaceutical focuses on enzyme replacement therapies for rare genetic disorders, competing in the same rare disease space as Orphazyme.
CRISPR Therapeutics
CRSP
Mkt Cap4.63B
CRISPR Therapeutics is involved in gene editing, a technology that has the potential to treat the genetic roots of many rare diseases.
Bluebird bio
BLUE
Mkt Cap114.8M
bluebird bio focuses on gene therapies for genetic diseases and cancer, competing in the rare disease treatment space.
Novo Nordisk
NVO
Mkt Cap445.94B
Novo Nordisk, while known for diabetes care, is expanding into treatments for rare blood disorders, showing its growing interest in the rare disease sector.
Pfizer
PFE
Mkt Cap169.83B
Pfizer has a broad portfolio that includes treatments for rare diseases, making it a competitor in the rare disease market space.

About

Pharmaceuticals: Major
Health Technology
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative rare diseases. The company offers heat stock proteins that focuses on the treatment of neurodegenerative diseases by harnessing the cell protective properties of the heat shock response, which protects cells from the accumulation of misfolded proteins, aggregated proteins, and dysfunctional lysosomes. Its lead candidate is the Arimoclomol, which is in clinical development for diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, and Inclusion Body Myositis. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
Show more...
CEO
Kim Stratton
Employees
1
Country
DK
ISIN
DK0062502894
WKN
000A2H7EV

Listings